Chemo plus two targeted drugs before surgery for HER2+ breast cancer
Part of Cancer clinical trials.
This trial tests whether giving a combination of two targeted drugs (pyrotinib and trastuzumab) along with standard chemotherapy before surgery can work better for HER2-positive breast cancer. It is for women whose cancer has not spread to distant organs and who have not yet had treatment for their cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75.
- Your breast cancer is HER2-positive (a specific protein that helps cancer grow).
- Your cancer is at an early stage that has not spread to other organs (Stage I–III, node-positive or larger tumors).
- You have not received prior anti-cancer treatment for this breast cancer.
- Your heart, kidney, and liver function are within normal limits, and you have no serious heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—pyrotinib, trastuzumab, and chemotherapy—to treat HER2-positive breast cancer that has not been treated before. HER2 is a protein found on some cancer cells; blocking it may help stop the cancer from growing.
This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.
This trial tests a combination of two targeted medicines (pyrotinib and trastuzumab) with chemotherapy to treat HER2-positive advanced breast cancer that has returned or spread after stopping trastuzumab.
This trial tests a treatment for early-stage HER2-positive breast cancer that is small and has not spread to lymph nodes. It aims to reduce the chance of cancer returning after surgery.
This trial tests a targeted drug called pyrotinib for women with HER2-positive breast cancer that hasn't spread far. It aims to see if adding this drug to standard treatment helps improve outcomes before and after surgery.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.